Navigation Links
Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
Date:4/17/2008

ects and widespread use can lead to development of bacterial resistance. Furthermore, diabetic ulcers are often associated with vascular disease and restricted peripheral blood flow (ischemia), which may render systemically acting antibiotics less effective. Infection can also spread to the bone (osteomyelitis), which is less well vascularized than soft tissue. Currently, there are no topically applied antibiotics marketed in the US that are specifically indicated for the treatment of infected diabetic foot ulcers and recent market research independently performed by L.E.K. Consulting forecast peak annual US sales revenues for CollaRx GENTAMICIN TOPICAL approaching US$270 million, when limiting the sales projections to diabetic foot indications only.

CollaRx GENTAMICIN TOPICAL is currently under investigation for the treatment and prevention of diabetic foot infections of varying severity in a series of multi-centred phase 2 clinical trials. The first of these trials, which commenced in late 2007, is investigating the product as a mono-antibiotic therapy for the treatment of mildly infected diabetic ulcers where the safety and efficacy of CollaRx GENTAMICIN TOPICAL will be compared to an orally administered antibiotic (the current standard of care). This second phase 2 trial will investigate the product as an adjunct to systemic antibiotic therapy for treating moderately infected ulcers, as defined according to Infectious Disease Society of America (IDSA) guidelines. The third phase 2 trial, planned to commence later this month, will investigate the product for the prevention of infection in diabetic foot ulcers.

Dr. Michael Myers, Innocoll's President and CEO commented, "Our Gentamicin-Collagen sponge is already used successfully in Europe and elsewhere as an adjunct for the treatment diabetic foot infections, where physicians have reported it can help to salvage limbs that may otherwise be amputated. Since there are currently no topical antibiotics o
'/>"/>

SOURCE Innocoll Inc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
2. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
3. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
5. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
6. ViroPharma Announces Discontinuation of HCV-796 Development
7. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
8. Free Prostate Cancer Seminar in Lake Ridge, VA: Dr. Charles Snuffy Myers Announces Vitamin D Clinical Trials
9. Phreesia Announces Clinical Initiative to Better Manage Symptoms of Parkinsons Disease
10. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
11. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... June 17, 2013 Vanda Pharmaceuticals Inc. ... data today at ENDO 2013, the Endocrine Society,s ... can entrain (synchronize) both melatonin and cortisol rhythms. ... the master body clock and address the circadian ... The SET (Safety and Efficacy of Tasimelteon) and ...
(Date:6/17/2013)... Quebec , June 17, 2013 Valeant Pharmaceuticals ... announced today that it has filed a preliminary prospectus supplement ... has today made a similar filing with securities regulatory authorities ... in connection with a public offering of its common ... "Offering"). The Company will also grant to the ...
(Date:6/17/2013)... NEW YORK , June 17, 2013 The ... and CEO, The Partnership at Drugfree.org :   ... to CNN that it was halting the sale of prescription ... of product we recognize that from time to time there ... are not our customer. As a result of this misinterpretation ...
Breaking Medicine Technology:Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4A Win for Families: Urban Outfitters Halts Prescription Drug Paraphernalia Product Sales 2
... UL, a world leader in advancing ... testing GmbH (MDT) and md registration support Ltd. (MDRS).  These ... UL,s Life and Health business unit.   MDT ... the medical services industry.  MDT specializes in clinical and non-clinical ...
... 2011 Apnex Medical, Inc., received investigational device exemption ... (FDA) to begin a clinical study to evaluate the ... System to treat obstructive sleep apnea (OSA). Data from ... Approval (PMA) application for the HGNS System to the ...
Cached Medicine Technology:UL Expands Presence in Medical Device Market With Acquisition of MDT 2UL Expands Presence in Medical Device Market With Acquisition of MDT 3Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea 2Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea 3
(Date:6/18/2013)... 2013 Seven-year-old Riley Salz of Encino, ... He receives 40 hours a week of applied behavior ... the Center for Autism and Related Disorders (CARD). Riley ... and has experienced remarkable progress, including learning to speak, ... Riley’s personal journey through autism is now featured in ...
(Date:6/18/2013)... Center clinical researchers have launched an innovative clinical ... the ability of a patient,s own stem cells ... arterial disease (PAD). , Led by Vik ... Hospitals Case Medical Center,s Harrington Heart & Vascular ... Reserve University School of Medicine, the clinical trial ...
(Date:6/18/2013)... More than 1.1 million people in the ... to the Centers for Disease Control and Prevention (CDC). Of ... support of National HIV Testing Day on June 27, Allsup, ... (SSDI) representation, the CDC and other organizations are raising awareness ... reports about 50,000 new HIV infections each year. Along with ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 myCNAjobs announces ... of free downloads, articles, and tips to the Caregiver ... to care for the 10,000+ retiring baby boomers each ... professional caregiver job resources has never been ... CNA job community, recently launched the first-ever free ...
(Date:6/18/2013)... A new $119 million industry is taking ... is redefining the way consumers get their seafood. ... culinary chefs on the Emerald Coast panhandle of Northwest ... and the promising industry of aquaculture. , The word ... strive to fully partake in the effort, especially when ...
Breaking Medicine News(10 mins):Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:myCNAjobs Adds New Resources to Growing Caregiver Career Center 2Health News:New $119 Million Industry Swimming Up the East Coast 2
... -- Men with low testosterone levels may be at increased ... a finding that challenges the current belief that testosterone is ... The study included 930 men with coronary artery disease ... of the study, low testosterone levels were noted in about ...
... ARBOR, Mich. Millions worldwide die each year because they ... States say they,d be willing to donate theirs after death ... Circulation, experts at the University of Michigan Cardiovascular ... they are removed for burial or cremation, for sterilization and ...
... Reinberg HealthDay Reporter , TUESDAY, Oct. 19 (HealthDay ... mothers and their infants from taking supplemental fish oil in ... finds no such benefit. In this large randomized, ... found no benefit from DHA in reducing levels of postpartum ...
... 19 (HealthDay News) -- Kidney-failure patients can continue taking a ... study showed they can increase the risk of stroke, U.S. ... and Drug Administration advisers voted 15-1, with one abstention, to ... disease who aren,t yet in need of dialysis, the ...
... Medicine investigated the role between adiponectin and leptin in ... issue of Hepatology , suggest that the protein ... of leptin, namely in hepatocellular carcinoma (HCC), and could ... Obesity is on the rise and is associated with ...
... Neuralstem, Inc. (NYSE Amex: CUR) updated the progress of ... company,s spinal cord stem cells in the treatment of ... Emory University in Atlanta, Georgia. The company announced that, ... non-ambulatory patients, the trial,s Safety Monitoring Board has unanimously ...
Cached Medicine News:Health News:Low Testosterone May Raise Risk of Early Death: Study 2Health News:Recycling pacemakers may alleviate burden of heart disease across the globe 2Health News:Recycling pacemakers may alleviate burden of heart disease across the globe 3Health News:Fish Oil Pills Don't Affect Postpartum Depression: Study 2Health News:Fish Oil Pills Don't Affect Postpartum Depression: Study 3Health News:Fish Oil Pills Don't Affect Postpartum Depression: Study 4Health News:FDA Advisers Back Anemia Drugs for Kidney Patients 2Health News:FDA Advisers Back Anemia Drugs for Kidney Patients 3Health News:FDA Advisers Back Anemia Drugs for Kidney Patients 4Health News:Adiponectin shows potential in blocking obesity-related carcinogenesis 2Health News:Neuralstem updates ALS clinical trial progress 2
Directional `E' and `C' test....
9" X 14" translucent plastic may be used with illuminated test cabinet or as a wall chart 20/200 to 20/15....
... The PowerLab/16SP is a high-performance recording unit ... science research applications that require up to ... and isolated tissue studies. The unit is ... to 200 000 samples per second continuously ...
Three Figure Worth Type Test, this test is used for determining diplopia, suppression or fusion in children. Sturdy chrome flashlight comes with red/green glasses. Requires 3 D batteries which are no...
Medicine Products: